A Conformational Escape Reaction of HIV-1 against an Allosteric Integrase Inhibitor.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
15 09 2020
Historique:
received: 23 03 2020
accepted: 23 06 2020
pubmed: 3 7 2020
medline: 22 12 2020
entrez: 3 7 2020
Statut: epublish

Résumé

HIV-1 often acquires drug-resistant mutations in spite of the benefits of antiretroviral therapy (ART). HIV-1 integrase (IN) is essential for the concerted integration of HIV-1 DNA into the host genome. IN further contributes to HIV-1 RNA binding, which is required for HIV-1 maturation. Non-catalytic-site integrase inhibitors (NCINIs) have been developed as allosteric IN inhibitors, which perform anti-HIV-1 activity by a multimodal mode of action such as inhibition of the IN-lens epithelium-derived growth factor (LEDGF)/p75 interaction in the early stage and disruption of functional IN multimerization in the late stage of HIV-1 replication. Here, we show that IN undergoes an adaptable conformational change to escape from NCINIs. We observed that NCINI-resistant HIV-1 variants have accumulated 4 amino acid mutations by passage 26 (P26) in the IN-encoding region. We employed high-performance liquid chromatography (HPLC), thermal stability assays, and X-ray crystallographic analysis to show that some amino acid mutations affect the stability and/or dimerization interface of the IN catalytic core domains (CCDs), potentially resulting in the severely decreased multimerization of full-length IN proteins (IN undermultimerization). This undermultimerized IN via NCINI-related mutations was stabilized by HIV-1 RNA and restored to the same level as that of wild-type HIV-1 in viral particles. Recombinant HIV-1 clones with IN undermultimerization propagated similarly to wild-type HIV-1. Our study revealed that HIV-1 can eventually counteract NCINI-induced IN overmultimerization by IN undermultimerization as one of the escape mechanisms. Our findings provide information on the understanding of IN multimerization with or without HIV-1 RNA and may influence the development of anti-HIV-1 strategies.

Identifiants

pubmed: 32611758
pii: JVI.00486-20
doi: 10.1128/JVI.00486-20
pmc: PMC7495394
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Anti-HIV Agents 0
HIV Integrase Inhibitors 0
Intercellular Signaling Peptides and Proteins 0
PSIP1 protein, human 0
Recombinant Proteins 0
Transcription Factors 0
lens epithelium-derived growth factor 0
HIV Integrase EC 2.7.7.-
p31 integrase protein, Human immunodeficiency virus 1 YY6481J2FF

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

J Biol Chem. 2012 Jun 15;287(25):21189-203
pubmed: 22535962
Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6057-61
pubmed: 7597080
Retrovirology. 2013 Nov 21;10:144
pubmed: 24261564
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8690-5
pubmed: 23610442
Lancet HIV. 2017 Jan;4(1):e31-e40
pubmed: 27863996
Antimicrob Agents Chemother. 2007 Jun;51(6):2143-55
pubmed: 17371811
Science. 1994 Dec 23;266(5193):1981-6
pubmed: 7801124
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):22-5
pubmed: 20057045
J Biomol Screen. 2012 Jun;17(5):618-28
pubmed: 22337657
J Biol Chem. 2017 Dec 1;292(48):19814-19825
pubmed: 28972144
Retrovirology. 2014 Nov 25;11:100
pubmed: 25421939
Lancet HIV. 2017 Aug;4(8):e349-e356
pubmed: 28501495
J Biomol Screen. 2010 Oct;15(9):1099-106
pubmed: 20855563
Antimicrob Agents Chemother. 2012 Aug;56(8):4365-74
pubmed: 22664975
Clin Infect Dis. 2010 Apr 1;50(7):1041-52
pubmed: 20192725
Nat Chem Biol. 2010 Jun;6(6):442-8
pubmed: 20473303
Clin Infect Dis. 2019 Jan 7;68(2):177-187
pubmed: 30052811
J Biol Chem. 2003 Jan 3;278(1):372-81
pubmed: 12407101
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
J Biol Chem. 2014 Sep 19;289(38):26430-40
pubmed: 25118283
J Biol Chem. 2012 May 11;287(20):16801-11
pubmed: 22437836
PLoS Biol. 2016 Dec 9;14(12):e1002584
pubmed: 27935939
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5426-30
pubmed: 8202502
Nat Protoc. 2007;2(9):2212-21
pubmed: 17853878
Retrovirology. 2013 May 30;10:57
pubmed: 23721378
J Virol Methods. 2016 Oct;236:196-206
pubmed: 27474494
Retrovirology. 2017 Nov 9;14(1):50
pubmed: 29121950
Adv Virus Res. 1999;52:411-26
pubmed: 10384245
J Virol. 2015 Oct;89(19):9765-80
pubmed: 26178982
Cell. 2016 Aug 25;166(5):1257-1268.e12
pubmed: 27565348
PLoS Pathog. 2009 Jul;5(7):e1000515
pubmed: 19609359
Science. 2017 Jan 6;355(6320):89-92
pubmed: 28059769
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
HIV AIDS (Auckl). 2018 Nov 02;10:215-224
pubmed: 30464642
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Antimicrob Agents Chemother. 2014 Jun;58(6):3233-44
pubmed: 24663024
Annu Rev Med. 2019 Jan 27;70:137-150
pubmed: 30355266
PLoS One. 2013 Sep 09;8(9):e74163
pubmed: 24040198
AIDS. 2014 May 15;28(8):1193-202
pubmed: 24556869
Retrovirology. 2015 Feb 12;12:16
pubmed: 25809198
PLoS Pathog. 2007 Mar;3(3):e47
pubmed: 17397262
PLoS Pathog. 2014 May 29;10(5):e1004171
pubmed: 24874515
J Virol. 2004 Dec;78(23):12735-46
pubmed: 15542626
J Org Chem. 2004 Nov 12;69(23):7822-9
pubmed: 15527257
J Biol Chem. 2013 May 31;288(22):15813-20
pubmed: 23615903

Auteurs

Tomofumi Nakamura (T)

Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Teruya Nakamura (T)

Priority Organization for Innovation and Excellence, Kumamoto University, Kumamoto, Japan.
Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.

Masayuki Amano (M)

Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Toshikazu Miyakawa (T)

Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Yuriko Yamagata (Y)

Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.

Masao Matsuoka (M)

Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Hirotomo Nakata (H)

Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan nakatahi@gpo.kumamoto-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH